Alentis Therapeutics, the Basel-based biotech developing breakthrough treatments for fibrotic diseases, announced Dr. Roberto Iacone as Chief Executive Officer.
Dr. Iacone is a physician-scientist with more than 15 years of experience in the life science industry. Before Alentis he was Global Head of Rare Diseases Research at Roche, and more recently an investor at Versant Ventures, where he co-founded Bright Peak Therapeutics and Ridgeline Therapeutics. While at Versant, Roberto was part of the leadership team that built Black Diamond Therapeutics from inception through to its NASDAQ IPO in three years.
Roberto brings his entrepreneurial thinking, drug development experience and leadership skills to advance Alentis’ portfolio into the clinic.
Here you can find the full press release published by Alentis
